

### **What is Claimed**

1. **(Cancelled)** A method of inhibiting skin lesions resulting from activation of proteinase-activated receptor-2 which comprises treating a site of inflammation prior to the formation of lesions with a therapeutically effective amount of composition containing a cromolyn compound to inhibit activation of said receptor by trypsin or tryptase.
2. **(Currently Amended)** The method of claim 1 wherein said composition comprises at least 0.5 to 5% by weight of said cromolyn compound.
3. **(Withdrawn)** The method of claim 1 wherein said cromolyn compound is selected from the group consisting of cromolyn sodium, disodium cromolyn and esters thereof.
4. **(Currently Amended)** The method of claim 1 wherein said composition contains stratum corneum penetrating agents.
5. **(Withdrawn)** The method of claim 4 wherein said penetrating agents are selected from the group consisting of cationic quaternary ammonium salts, cyclodextrin and an arginine containing amino acids.
6. **(Currently Amended)** The method of claim 1 wherein said composition forms an occlusive bandage.

7. **(Cancelled)** The method of claim 1 wherein said composition contains a corticosteroid.
8. **(Cancelled)** A method for preventing the formation of lesions in a patient suffering from atopic dermatitis which comprises applying the composition of claim 1 prior to the formation of lesions.
9. **(Cancelled)** The method of claim 8 wherein said composition is applied when inflammation is indicated.
10. **(Cancelled)** The method for preventing the formation of lesions in a patient having an acute inflammatory response to prevent activation of proteinase-activated receptor-2 which comprises administering the composition of claim 1.
11. **(Currently Amended)** The method of claim 4 13 wherein the cromolyn compound is cromolyn sodium.
12. **(Currently Amended)** The method of claim 4 13 wherein said penetrating agent is cyclodextrin.
13. **(New)** A method for treating a patient suffering from diaper rash or decubitus ulcers which comprises topically administering a therapeutically effective amount of a cromolyn

compound in a pharmaceutically acceptable carrier to the site of the diaper rash or decubitus ulcers.